Role of anti-craving drugs baclofen and topiramate in the maintenance of abstinence in alcohol dependence syndrome


Alcohol dependence syndrome

How to Cite

Kaul, V., & Bahadur Rai, P. . (2022). Role of anti-craving drugs baclofen and topiramate in the maintenance of abstinence in alcohol dependence syndrome. Journal of Kathmandu Medical College, 11(3), 182–188. Retrieved from


Background: Alcohol craving is psychological condition related to motivation. Craving is risk factor for relapse in alcohol dependence syndrome. No gold standard therapy is available; many therapeutic agents are under various evaluation stages.

Objectives: To evaluate role of anti-craving drugs baclofen and topiramate in maintenance of abstinence in alcohol dependence syndrome

Methods: From March to October 2018, an open-label interventional study with 70 sample size was conducted at Nobel Medical College, following ethical clearance. Age range for inclusion was 20-60, with no history of psychotropic use, whereas history of psychiatric illness and use of substance, excluding nicotine were excluded. After written informed consent patients were admitted for detoxification, and after detoxification, anti-craving therapy was started with topiramate and baclofen and asked for follow-up at two, four, and six weeks. Clinical withdrawal assessment scale was used for withdrawal symptoms and obsessive-compulsive drinking scale (OCDS) for progress in craving. Baclofen at 20 mgs/day, topiramate at 50 mgs/day, were prescribed and increased as required at follow-up.

Results: Maximum daily dose of baclofen was 24.29 ± 2.19 mg and topiramate 120 ± 33.21 mg. Baclofen group patients had significant improvement in second week (OCDS T score 16.41± 9.52) while topiramate group showed significant improvement (OCDS T score 17.70 ± 7.57) after four weeks. Major side effects were tremors 8.10% in topiramate group, headache was 5.40% in both groups.

Conclusion: Baclofen and topiramate were equally effective at six weeks for controlling cravings. Baclofen started to show significant improvements after two weeks of trial.



Room R, Babor T, Rehm J. Alcohol and public health. Lancet. 2005;365:519–30. [PubMed |Full Text| DOI]

Oxford Dictionary, Oxford University Press ©2022. [Oxford Dictionary]

Sinha R, O’Malley SS. Craving for alcohol: Findings from the clinic and the laboratory. Alcohol and alcoholism. 34; 223-30. [PubMed | Full Text | DOI]

Witkiewitz, K., Bowen, S., & Donovan, D. M. Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence. Journal of Consulting and Clinical Psychology. 2011;79(1);54–63. [Pub Med | Full Text |DOI]

Verheul, R., Van Den Brink, W., & Geerlings, P. A three-pathway psychological model of craving for alcohol. Alcohol and Alcoholism.1999;34;197–222 [PubMed | Full Text |DOI]

Koob GF, Volkow ND. Neurobiology of addiction: A neurocircuitry analysis. Lancet Psychiatry. 2016 Aug;3(8):760-773. [PubMed | Full Text | DOI]

Cibin, M. (1993). Craving: Physiopathology and clinical aspects. Alcologia, European Journal of Alcohol Studies.5;257–260.

Sullivan, J.T.; Sykora, K.; Schneiderman, J.; Naranjo, C.A.; and Sellers, E.M. Assessment of alcohol withdrawal: The revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). British Journal of Addiction. 84:1353-1357, 1989.[ PubMed | Full Text |DOI]

Anton RF. Obsessive-compulsive aspects of craving: development of the Obsessive Compulsive Drinking Scale. Addiction. 2000 Aug;95 Suppl 2:S211-7.[PubMed | Full Text |DOI]

Hesler RK, Miller WR, editors. Handbook of Alcoholism Treatment Approaches: Effective Alternatives. 2nd ed. Elmsford, NY: Pergamon Press. [Handbook of alcoholism: Treatement and approaches]

Dall Aglio C, Caputo F, Baudanza P, Castelli E, Marsigli L, Addolorato G, et al. Short and long term treatment of alcohol dependence. Alcol Eur J Alcohol Stud. 1997; 9:61–4. [Full Text]

Lobo IA, Harris RA. GABAA receptors and alcohol. Pharmacol Biochem Behav. 2008; 90:90–4. [PubMed | Full Text]

Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Topiramate for treating alcohol dependence: A randomized controlled trial. JAMA. 2007; 298:1641–51. [PubMed |Full Text]

Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 1996; 347:1438–42. [PubMed | Full Text]

Naranjo CA, Poulos CX, Bremner KE, Lanctot KL. Fluoxetine attenuates alcohol intake and desire to drink. Int Clin Psychopharmacol. 1994; 9:163–72. [PubMed| Full Text |DOI]

Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992; 49:876–80. [PubMed |Full Text |DOI]

Colombo G, Addolorato G, Agabio R, Carai MA, Pibiri F, Serra S, et al. Role of GABA (B) receptor in alcohol dependence: Reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotox Res. 2004; 6:403–14. [PubMed | Full Text]

Weiss F, Porrino LJ. Behavioral neurobiology of alcohol addiction: Recent advances and challenges. J Neurosci. 2002; 22:3332–7. [PubMed | Full Text |DOI ]

Bowery NG, Hudson AL, Price GW. GABAA and GABAB receptor site distribution in the rat central nervous system. Neuroscience. 1987; 20:365–83. [PubMed |Full Text|DOI]

Yoshida M, Yokoo H, Tanaka T, Emoto H, Tanaka M. Opposite changes in the mesolimbic dopamine metabolism in the nerve terminal and cell body sites induced by locally infused baclofen in the rat. Brain Res. 1994; 636:111–4. [PubMed |Full Text |DOI]

Xiao C, Shao XM, Olive MF, Griffin WC, 3rd, Li KY, et al. Ethanol facilitates glutamatergic transmission to dopamine neurons in the ventral tegmental area. Neuropsychopharmacology. 2009; 34:307–18. [PubMed |Full Text | DOI]

Addolorato, G., Caputo, F., Capristo, E., Colombo, G., Gessa, G.Let al. 2000. Ability of baclofen in reducing alcohol craving and intake:II—Preliminary clinical evidence. Alcoholism: Clinical and Experimental Research, 24(1):67-71. [|Full Text |DOI]

Addolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Vonghia, L., et al. 2007. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. The Lancet, 370(9603): 1915-1922. [PubMed | Full Text| DOI ]

Esmeralda Capristo, Marco Domenicali, Mauro Bernardi, Luigi Janiri, Roberta Agabio, et al. Baclofen efficacy in reducing alcohol craving and intake : A preliminary double blind randomized controlled study, Alcohol and Alcoholism, September 2002.37( 5); 504–508. [PubMed |Full Text | DOI]

Paparrigopoulos, T., Tzavellas, E., Karaiskos, D. et al. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry. 2011.11; 41. [ Pub Med |Full Text |DOI]

Olmsted CL, Kockler DR. Topiramate for Alcohol Dependence. Annals of Pharmacotherapy. 2008;42(10):1475-1480.[ |Full Text |DOI]

Flórez G, Saiz PA, García-Portilla P, Alvarez S, Nogueiras L, Bobes J. Topiramate for the treatment of alcohol dependence: comparison with naltrexone. Eur Addict Res. 2011;17(1):29-36. [PubMed | Full Text |DOI]

Palpacuer, C., Duprez, R., Huneau, A., Locher, C., Boussageon, et al. (2018) Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: A systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction, 113: 220– 237. [PubMed | Full Text |DOI]